NCT04120701招募中3 期
CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 1,980
- 试验地点
- 2
- 主要终点
- 3-year Disease-Free Survival in ctDNA positive patients
研究概览
简要总结
The objective of CIRCULATE trial is to improve care of patients after colon tumor surgery, based on an innovative marker: circulating tumor DNA.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent obtained prior to any study specific procedures
- •Age ≥ 18 years and ≤ 75 years
- •Histologically confirmed stage II colon and high rectum adenocarcinoma excluding low and medium rectal cancers (tumor location ≥ 12 cm from the anal verge by endoscopy and/or above the peritoneal reflection at surgery are still eligible), without gross or microscopic evidence of residual disease after surgery with curative intent. Pathology report must be faxed to CRGA just after patient's randomization.
- •At least 12 lymph nodes analyzed
- •Patient with MSI + tumors can be included
- •All patients must have been discussed in multidisciplinary meetings with a decision of not performing adjuvant chemotherapy
- •No metastatic disease on CT-Scan and/or liver MRI done within 3 months before randomization.
- •Randomization planned up to 7 weeks after curative R0 resection
- •WHO performance Status < 2
- •No prior chemotherapy for colo-rectal cancer
- •No prior abdominal or pelvic irradiation for colo-rectal cancer
- •Life expectancy of ≥ 5 years
- •Adequate haematological function: with neutrophils ≥ 1,500 /mm3, platelet count ≥ 100,000/mm3, hemoglobin ≥ 9 g/dL (5,6 mmol/l)
- •Total bilirubin ≤ 1.5 x ULN (upper limit of normal)
- •ASAT and ALAT ≤ 2.5 x ULN
- •Alkaline phosphatase ≤ 2.5 x ULN
- •Serum creatinine ≤ 120 µmol/L or creatinine clearance ≥50 ml/min according MDRD (Modification of Diet in Renal Disease)
- •Carcinoembryogenic antigen (CEA) ≤ 1.5 x ULN after surgery (during screening period)
- •Negative pregnancy test for registration(for women of childbearing age)
- •Patient affiliated to a social security system
排除标准
- •T4b tumors
- •Peripheral neuropathy > grade 1
- •Comorbidity influencing the 5 year patients' survival including clinically relevant cardiovascular disease,
- •Ischemic myocardial infarction in the last year and/or unstable ischemic cardiopathy,
- •Participation to another interventional study for postoperative therapy
- •Partial or complete DPD deficiency
- •Legal incapacity or physical, psychological social or geographical status interfering with the patient's ability to sign the informed consent or to finish the study
- •Medical history of other concomitant or previous malignant disease, except adequately treated in situ carcinoma of the uterine cervix, basal or squamous cell carcinoma of the skin, or cancer in complete remission for ≥ 5 years,
- •Lack of effective contraception in patients (men and/or women) of childbearing age, pregnant or breastfeeding women. Women of childbearing potential should agree to use a method of contraception during treatment of the trial and at least 4 months after discontinuation of oxaliplatin therapy and at least 30 days after discontinuation of 5-fluorouracil. Men must agree to use a method of contraception during treatment and at least 6 months after stopping oxaliplatin therapy and at least 3 months after stopping 5-fluorouracil.
研究组 & 干预措施
Chemotherapy
Experimental
干预措施: mFOLFOX6 (Drug)
结局指标
主要结局
3-year Disease-Free Survival in ctDNA positive patients
时间窗: 3-years
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
招募中
3 期
Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II EvaluationColon Cancer Stage IINCT04089631Technische Universität Dresden4,812
招募中
2 期
OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal CancerMetastatic CancerColorectal CancerNCT04680260Karen-Lise Garm Spindler350
招募中
不适用
Circulating Tumor DNA in Patients Summoned for Colonoscopy; - a Liquid Biopsy for Detection, Characterization, Individualized Treatment and Follow-up of Colorectal CancerColorectal CancerColorectal AdenomaNCT06307938Helse Nord-Trøndelag HF3,000
暂停
2 期
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)Non-small Cell Lung Cancer Stage INon-small Cell Lung Cancer Stage IINon-small Cell Lung Cancer Stage IIINon-small Cell Lung CancerNCT04585477Stanford University80
Enrolling By Invitation
不适用
KIDNEY-PAGER: Analysis of Circulating Tumor DNA as a Biomarker in Renal Cancer - an Observational TrialRenal CancerNCT06145139University of Aarhus500